Organon & (US:OGN)2024-10-31 16:29Financial Performance - Organon's Q3 2024 revenue reached $1.6 billion, a 5% increase ex-FX [7] - Adjusted EBITDA for Q3 2024 was $459 million, including $51 million in IPR&D and milestone expenses [7] - The company is on track to deliver approximately $1 billion of free cash flow before one-time spin-related costs for the full year 2024 [16] - Net leverage ratio was approximately 40x as of September 30, 2024 [17] Segment Performance - Women's Health revenue in Q3 2024 was $440 million, a 5% increase (6% ex-FX) compared to Q3 2023 [11, 34] - Nexplanon revenue increased by 10% (11% ex-FX) to $243 million in Q3 2024 [11] - NuvaRing revenue decreased by 45% to $23 million due to generic competition [11] - Jada revenue increased by 24% to $16 million in Q3 2024 [11] - Biosimilars revenue in Q3 2024 was $165 million, a 16% increase (17% ex-FX) compared to Q3 2023 [12, 34] - Hadlima revenue was $40 million in Q3 2024 [12] - Ontruzant revenue decreased by 49% to $20 million [12] - Established Brands revenue in Q3 2024 was $951 million, a 2% increase (3% ex-FX) compared to Q3 2023 [13, 34] Guidance - Full year 2024 revenue is expected to be between $6375 billion and $6425 billion, representing a 31% to 38% increase at constant currency [18, 23] - Adjusted EBITDA margin for full year 2024 is revised to 300% - 310% [29] - R&D expenses for full year 2024 are expected to be between $510 million and $550 million, including $81 million in IPR&D expenses [28, 27]